miR-137, a new target for post-stroke depression?

Neural Regeneration Research

Volumn 8, Issue 26, 2013, Pages 2441-2448

  Zhao, Li Xia ^a,b   Li, Hua Zi ^b   Guo, Rui You ^b   Ma, Teng ^b   Hou, Rong Yao ^b   Ma, Xiao Wei ^b   Du, Yi Feng ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Brain injury; Cerebrovascular disease; Grin2a; MicroRNA; miR 137; Neural regeneration; Neuroregeneration; Post stroke depression

Indexed keywords

LENTIVIRUS VECTOR; MICRORNA 137; MICRORNA 137 ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; RNA; SUCROSE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BLOOD; BRAIN; BRAIN VENTRICLE; CELL STRAIN HEK293; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEPRESSION; GENE EXPRESSION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OPEN FIELD TEST; PC12 CELL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STRESS; WESTERN BLOTTING;

EID: 84888386831     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2013.26.005     Document Type: Article

References (48)

1. Van Wynsberghe PM, Chan SP, Slack FJ, et al. Analysis of microRNA expression and function. Methods Cell Biol. 2011;106:219-252.
2. Berezikov E. Evolution of microRNA diversity and regula-tion in animals. Nat Rev Genet. 2011;12(12):846-860.
3. Bilsland AE, Revie J, Keith W. MicroRNA and senescence: the senectome, integration and distributed control. Crit Rev Oncog. 2013;18(4):373-390.
4. De Cecco L, Dugo M, Canevari S, et al. Measuring mi-croRNA expression levels in oncology: from samples to data analysis. Crit Rev Oncog. 2013;18(4): 273-287.
5. Xu L, Yang BF, Ai J. MicroRNA transport: a new way in cell communication. J Cell Physiol. 2013;228(8):1713-1719.
6. Smalheiser NR, Lugli G, Rizavi HS, et al. MicroRNA ex-pression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One. 2012; 7(3):e33201.
7. Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, et al. Blood microRNA changes in depressed patients during antide-pressant treatment. Eur Neuropsychopharmacol. 2013; 23(7):602-611.
8. Baudry A, Mouillet-Richard S, Schneider B, et al. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science. 2010;329(5998): 1537-1541.
9. Mouillet-Richard S, Baudry A, Launay JM, et al. Micro-RNAs and depression. Neurobiol Dis. 2012;46(2):272-278.
10. O'Connor RM, Dinan TG, Cryan JF. Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression. Mol Psychiatry. 2012;17(4):359-376.
11. Tan KS, Armugam A, Sepramaniam S, et al. Expression profile of MicroRNAs in young stroke patients. PLoS One. 2009;4(11):e7689.
12. Jeyaseelan K, Lim KY, Armugam A. MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke. 2008;39(3):959-966.
13. Dharap A, Vemuganti R. Ischemic pre-conditioning alters cerebral microRNAs that are upstream to neuroprotective signaling pathways. J Neurochem. 2010;113(6):1685-1691.
14. Geekiyanage H, Jicha GA, Nelson PT, et al. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp Neurol. 2012;235(2):491-496.
15. Smrt RD, Szulwach KE, Pfeiffer RL, et al. MicroRNA miR-137 regulates neuronal maturation by targeting ubi-quitin ligase mind bomb-1. Stem Cells. 2010;28(6):1060-1070.
16. Cummings E, Donohoe G, Hargreaves A, et al. Mood congruent psychotic symptoms and specific cognitive deficits in carriers of the novel schizophrenia risk variant at MIR-137. Neurosci Lett. 2013;532:33-38.
17. Kwon E, Wang W, Tsai LH. Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets. Mol Psychiatry. 2013;18(1):11-12.
18. Mozhui K, Karlsson RM, Kash TL, et al. Strain differences in stress responsivity are associated with divergent amygdala gene expression and glutamate-mediated neuronal excitability. J Neurosci. 2010;30(15):5357-5367.
19. Reutlinger C, Helbig I, Gawelczyk B, et al. Deletions in 16p13 including GRIN2A in patients with intellectual disability, various dysmorphic features, and seizure disorders of the rolandic region. Epilepsia. 2010;51(9):1870-1873.
20. Cherlyn SY, Woon PS, Liu JJ, et al. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. Neurosci Biobehav Rev. 2010;34(6):958-977.
21. Sanhueza M, Lisman J. The CaMKII/NMDAR complex as a molecular memory. Mol Brain. 2013;6:10.
22. Bliss TV, Collingridge GL. Expression of NMDA receptor-dependent LTP in the hippocampus: bridging the divide. Mol Brain. 2013;6:5.
23. Paoletti P. Molecular basis of NMDA receptor functional diversity. Eur J Neurosci. 2011;33(8):1351-1365.
24. Spalloni A, Nutini M, Longone P. Role of the N-methyl-D-aspartate receptors complex in amyotrophic lateral sclerosis. Biochim Biophys Acta. 2013;1832(2):312-322.
25. Santangelo RM, Acker TM, Zimmerman SS, et al. Novel NMDA receptor modulators: an update. Expert Opin Ther Pat. 2012;22(11):1337-1352.
26. Szakacs R, Janka Z, Kalman J. The "blue" side of gluta-matergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression. Neuropsychopharmacol Hung. 2012;14(1):29-40.
27. Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475(7354):91-95.
28. Castillo CS, Schultz SK, Robinson RG. Clinical correlates of early-onset and late-onset poststroke generalized anxiety. Am J Psychiatry. 1995;152(8):1174-1179.
29. Isaev NK, Stelmashook EV, Plotnikov EY, et al. Role of acidosis, NMDA receptors, and acid-sensitive ion channel 1a (ASIC1a) in neuronal death induced by ischemia. Biochemistry (Mosc). 2008;73(11):1171-1175.
30. Marini AM, Popolo M, Pan H, et al. Brain adaptation to stressful stimuli: a new perspective on potential therapeutic approaches based on BDNF and NMDA receptors. CNS Neurol Disord Drug Targets. 2008;7(4):382-390.
31. Hei MY, Kuang SJ. N-methyl-D-aspartate receptor-1 activation and neonatal brain injury. Zhongguo Dang Dai Er Ke Za Zhi. 2008;10(3):431-434.
32. Benquet P, Gee CE, Gerber U. Transient brain ischemia: NMDA receptor modulation and delayed neuronal death. Med Sci (Paris). 2008;24(2):185-190.
33. Villmann C, Becker CM. On the hypes and falls in neuro-protection: targeting the NMDA receptor. Neuroscientist. 2007;13(6):594-615.
34. Verkhratsky A, Kirchhoff F. NMDA Receptors in glia. Neuroscientist. 2007;13(1):28-37.
35. Cam E, Yulug B, Ozan E. MK 801: a possible neuropro-tective agent by poststroke depression? J Neuropsychia-try Clin Neurosci. 2008;20(3):367-368.
36. Robinson RG, Jorge RE, Clarence-Smith K, et al. Double-blind treatment of apathy in patients with poststroke depression using nefiracetam. J Neuropsy-chiatry Clin Neurosci. 2009;21(2):144-151.
37. Cho SI, Park UJ, Chung JM, et al. Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010;23(9):549-556.
38. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev. 2007;54(1):34-66.
39. Catarzi D, Colotta V, Varano F. Competitive Gly/NMDA receptor antagonists. Curr Top Med Chem. 2006;6(8):809-821.
40. Gogas KR. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol. 2006; 6(1):68-74.
41. The Ministry of Science and Technology of the People's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.
42. Hahn CD, Manlhiot C, Schmidt MR, et al. Remote ischemic per-conditioning: a novel therapy for acute stroke? Stroke. 2011;42(10):2960-2962.
43. Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84-91.
44. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology. 2005;52(2):90-110.
45. Nishida F, Morel GR, Hereñú CB, et al. Restorative effect of intracerebroventricular insulin-like growth factor-I gene therapy on motor performance in aging rats. Neuros-cience. 2011;177:195-206.
46. Wang SH, Zhang ZJ, Guo YJ, et al. Decreased expression of serotonin 1A receptor in the dentate gyrus in association with chronic mild stress: a rat model of post-stroke depression. Psychiatry Res. 2009;170(2-3):245-251.
47. Duan Q, Wang X, Gong W, et al. ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human he-patocellular cancer. PLoS One. 2012;7(2):e31518.
48. Zhang SH, Wang CJ, Shi L, et al. High Expression of FLOT1 Is Associated with Progression and Poor Prognosis in Hepatocellular Carcinoma. PLoS One. 2013;8(6): e64709.